Fred Alger Management, an investment management company, released its "Alger Mid Cap Focus Fund" second-quarter 2026 investor letter. A copy of the letter can be downloaded here. US equities strongly rebounded in the second quarter, with the S&P 500 Index returning 15.2%. A ceasefire between the United States and Iran and accelerated investment in artificial intelligence (AI) fueled market optimism in the quarter, driving the Information Technology and Industrials sectors forward, while Energy and Utilities lagged due to falling oil and gas prices. Despite discussions about AI disruption, opportunities are identified within sectors adopting the technology as it enters its agentic phase. The Alger Mid Cap Focus Fund's Class A shares outperformed the Russell Midcap Growth Index in the quarter, driven by strong performances in Information Technology and Health Care, while Communication Services and Consumer Discretionary detracted from the performance. In addition, please check the Fund's top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Alger Mid Cap Focus Fund highlighted Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focusing on developing therapies for patients with serious and rare diseases. On July 17, 2026, Insmed Incorporated (NASDAQ:INSM) closed at $108.32 per share, reflecting a market capitalization of $23.49 billion. Insmed Incorporated (NASDAQ:INSM) posted a one-month return of 9.85%, and its shares gained 5.39% over the past 52 weeks.
Alger Mid Cap Focus Fund stated the following regarding Insmed Incorporated (NASDAQ:INSM) in its Q2 2026 investor update:
"Insmed Incorporated (NASDAQ:INSM), GFL Environmental Inc, and Karman Holdings Inc. were among the top detractors from performance. Insmed is a commercial-stage biopharmaceutical company focused on respiratory, inflammatory, pulmonary, and rare disease treatments, with an approved portfolio that includes Brinsupri and Arikayce. The company's opportunity is tied to expanding adoption of its commercial products while advancing a pipeline aimed at areas of meaningful unmet medical need. During the quarter, shares detracted from performance despite headline results that were generally better than expected, as investors focused on early launch dynamics for Brinsupri. Concerns centered on patient additions, discontinuation rates, and compliance trends, which raised questions about the quality and durability of the launch. While these issues pressured the stock, management has begun providing greater detail around launch dynamics, and we believe improved execution and additional data could help restore investor confidence over time."
Source: Yahoo Finance Top News — This article was automatically imported from the source. Read full article at original source →
